*2.2. Study Selection and Eligibility*

Only RCTs were enrolled to avoid potential selection and confounding bias [21,23]. Studies comparing oral/topical JAK inhibitors against placebo were included with no

defined limitations on age, sex, ethnicity, AD severity, or treatment duration of participants. Case reports, letters, editorials, review articles, conference abstracts, and in vivo studies involving animals were excluded.
